Dare Bioscience Inc
$ 1.88
-13.76%
05 Jun - close price
- Market Cap 28,161,500 USD
- Current Price $ 1.88
- High / Low $ 2.19 / 1.86
- Stock P/E N/A
- Book Value 0.05
- EPS -0.91
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -25.43 %
- 52 Week High 3.78
- 52 Week Low 1.27
About
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$9.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-12 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.2 | -0.1006 | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.88 | -0.07 | -0.06 | -0.09 | -0.1 |
| Estimated EPS | -0.305 | -0.42 | 0.02 | 0.03 | -0.58 | -0.6333 | -0.73 | 0.02 | -0.06 | -0.1 | -0.1 | -0.1 |
| Surprise | 0.105 | 0.3194 | -0.3 | -0.48 | 0.08 | -0.0167 | 0.18 | -0.9 | -0.01 | 0.04 | 0.01 | 0 |
| Surprise Percentage | 34.4262% | 76.0476% | -1500% | -1600% | 13.7931% | -2.637% | 24.6575% | -4500% | -16.6667% | 40% | 10% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-06-04 12:39:56
Daré Bioscience is launching Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance and support vaginal comfort, marking the company's first direct consumer product revenue. This targeted non-hormonal approach uses a vagina-specific Limosilactobacillus fermentum LF5 strain, backed by clinical research and over 30 years of probiotic study. The launch signifies a commercial milestone for Daré, alongside advancements in its pipeline for DARE-HPV and its investigational contraceptive, Ovaprene®.
2026-06-04 11:39:43
Daré Bioscience (NASDAQ: DARE) has announced the upcoming U.S. launch of Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance and support vaginal comfort. This launch marks a significant transition for Daré Bioscience, moving it from a development-stage biotech to a revenue-generating women's health company, with first direct consumer product revenue expected in June 2026. To celebrate, a limited-time offer provides a 30% discount and free shipping for those who sign up for launch updates.
2026-06-04 08:10:00
Daré Bioscience, Inc. announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance and support vaginal comfort. This launch marks a significant milestone as the company anticipates generating its first direct consumer product revenue in June 2026, transitioning into a revenue-generating women's health company. Flora Sync LF5™ will be marketed under the DARE to RESTORE™ brand and is formulated with a clinically studied probiotic strain, Limosilactobacillus fermentum LF5, specifically for vaginal health.
2026-05-29 22:39:39
DARE Bioscience Inc. (NASDAQ: DARE) stock is currently trading at $2.14, reflecting a decrease of 2.28% today and 31.19% over the past month. The company, focused on women's reproductive health products, received a technical rating of 5/10 and a fundamental rating of 2/10 from ChartMill. Analysts have an average price target of $10.46, suggesting a significant potential increase of 388.55%.
2026-05-28 08:39:41
Daré Bioscience announced interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free intravaginal contraceptive. The Data Safety Monitoring Board recommended the study continue without modification after reviewing data that showed a 9% pregnancy rate, aligning with expectations. The company also reported on a recently completed Regulation A offering and highlighted improvements in capital efficiency.
2026-05-26 20:40:20
Daré Bioscience Inc. announced it received a second $1.0 million tranche from the NIH under a grant for DARE-HPV, bringing total funding to $2.0 million for its investigational human papillomavirus treatment. The clinical-stage biopharmaceutical company, with a $35.5 million market cap, is conducting a Phase 2 clinical study and expects topline data in 2027, despite facing liquidity challenges and a negative free cash flow. Analysts have set price targets significantly above the current stock price, reflecting optimism about the company’s pipeline.
